Get started
Author

Y. Panaseykin

Observed names: J. A. Panaseykin, Panaseykin, Yury, Y. A. Panaseykin, Y.A. Panaseykin, Yu. A. Panaseikin, Yu. A. Panaseykin, Yu. Panaseykin, Yu. А. Panaseykin, Yu.A. Panaseykin, Yury Panaseykin, Панасейкин Ю.А., Ю. А. Панасейкин, Ю.А. Панасейкин, Юрий Панасейкин
ORCID: 0000-0003-4537-0534
Observed ORCID: 0000-0003-4537-0534
OpenAlex ID: A5077010949
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
2021 · Marcia S Brose, Yury Panaseykin, et al. · The Journal of Clinical Endocrinology & Metabolism · 92
PDF
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
2020 · M.S. Brose, Y. Panaseykin, et al. · Annals of Oncology · 13
Photodynamic therapy treatment of oral cavity cancer in patients with comorbidities
2023 · Y. A. Panaseykin, V. N. Kapinus, et al. · Biomedical Photonics · 8
PDF
Possibilities of photodynamic therapy in the treatment of malignant tumors of the oral cavity
2021 · Y. A. Panaseykin, E. V. Filonenko, et al. · Biomedical Photonics · 8
PDF
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
2022 · Matthew H. Taylor, Sophie Leboulleux, et al. · Cancer Medicine · 7
PDF
Photodynamic therapy in treatment of squamous cell carcinoma of oral cavity with chlorine e6 photosensitizer with long-term follow up
2024 · Y. A. Panaseykin, V. N. Kapinus, et al. · Biomedical Photonics · 6
Chemoradiotherapy for Oral Cancer Using Hyperfractionated Radiation Schedule
2021 · M. U. Radzhapova, I. A. Gulidov, et al. · Siberian Journal of Oncology · 4
PDF
Sentinel lymph node biopsy experience in squamous cell carcinoma of the oral mucosa сT1–2N0M0
2023 · F. E. Sevryukov, V. V. Polkin, et al. · Head and neck tumors (HNT) · 3
PDF
A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer
2022 · M. S. Brose, Yu. Panaseykin, et al. · Head and neck tumors (HNT) · 3
PDF
Osteoradionecrosis of the facial skull: current evidence (literature review)
2023 · V.V. Polkin, P.A. Isaev, et al. · Radiation and Risk Bulletin of the National Radiation and Epidemiological Registry · 2
PDF
Surgical treatment of metastases of medullary thyroid cancer in the liver
2022 · Павел Исаев, Вячеслав Полькин, et al. · Voprosy Onkologii · 2
PDF
Синдром Гийена– Барре У Больных После Хирургического Вмешательства На Щитовидной Железе
2021 · МРНЦ им А.Ф.Цыба — филиал ФГБУ «НМИРЦ» Минздрава России, А.А. Ильин, et al. · IEEE Lasers and Electro-Optics Society Annual Meeting (LEOS) · 2
PDF
Isolated neurofibroma of the tongue
2021 · F.E. Sevrukov, P.A. Isaev, et al. · Stomatology · 2
Efficacy of external beam radiotherapy and targeted therapy with vandenanib in patients with inoperable and progressive medullary thyroid cancer
2018 · A. D. Kaprin, S. A. Ivanov, et al. · Head and neck tumors (HNT) · 2
PDF
Selpercatinib – a new option for a precision approach to the treatment of medullary thyroid cancer
2025 · A. K. Plugar, N. V. Severskaya, et al. · Head and neck tumors (HNT) · 1
PDF
Preventive Transoral Endoscopic Thyroidectomy by Vestibular Approach in 6-Year-Old Patient with the High-Risk RET C634R Germline Mutation
2023 · Yury Panaseykin, Vyacheslav Polkin, et al. · Case Reports in Oncology · 1
1746P Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN)
2021 · M.H. Taylor, S. Leboulleux, et al. · Annals of Oncology · 1
PDF
Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
2020 · F. S. Sevryukov, E. V. Borodavina, et al. · Head and neck tumors (HNT) · 1
PDF
The efficacy of selperkatinib in the first and subsequent lines of targeted therapy in unresectable progressive medullary thyroid cancer with a mutation in the gene RET
2026 · V. V. Polkin, Yu. A. Panaseykin, et al. · Head and neck tumors (HNT)
PDF
Вторичное Поражение Щитовидной Железы
2024 · А. А. Ильин, В. В. Полькин, et al. · Высшая школа: научные исследования
PDF
“Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use
2023 · E. V. Borodavina, A. Yu. Shurinov, et al. · Head and neck tumors (HNT)
PDF
Консервативное Лечение Абсцессов Щитовидной Железы
2023 · А. А. Ильин, В. В. Полькин, et al. · Высшая школа: научные исследования
PDF
Solitary metastasis of the clear cell variant of renal cell carcinoma into the thyroid gland
2019 · F. E. Sevrukov, P. A. Isaev, et al. · Head and neck tumors (HNT)
PDF
Комбинированное лечение нерезектабельного и прогрессирующего медуллярного рака щитовидной железы (МРЩЖ)
2018 · Ф Е Севрюков, I. S. Pimonova, et al. · CyberLeninK (CyberLeninka)
PDF
68. Sentinel lymph node biopsy in papillary thyroid carcinoma in decision for selective modified lateral neck dissection
2016 · I. Markovic, M. Goran, et al. · European Journal of Surgical Oncology
Works count: 31
Citation count: 158
H-index: 6
I10-index: 2
Year
Topic
Type